论文信息 - Combination treatment options for small-cell lung cancer. - 字舞流文

Combination treatment options for small-cell lung cancer.

N. Horita | S. Katakura | Kaneko Takeshi

[1] N. Reinmuth,et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. , 2020, The Lancet. Oncology.

[2] N. Horita,et al. Systematic review of first-line chemotherapy for chemo-naïve extensive-stage small-cell lung cancer: network meta-analysis , 2020, Therapeutic advances in medical oncology.

[3] A. Mansfield,et al. First‐Line Atezolizumab plus Chemotherapy in Extensive‐Stage Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[4] L. Ek,et al. Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5] K. Mori,et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. , 2002, The New England journal of medicine.